Why is Monopar Therapeutics stock down today? Key support levels to watch

Traders Union
All News
Stocks
Monopar Therapeutics drops 2.93% today

Highlights

MNPR/USD maintains a strong bullish technical profile, trading well above short, medium, and long-term trend indicators.
Mixed momentum signals and overbought conditions suggest buyer dominance but highlight risk of near-term volatility and potential pullback.
Forecast projects a $106.20–$116.32 range over the next 2-3 days, with a 65% probability of further upside.

Mixed momentum as technical supports limit overbought pressures

On the hourly chart, MNPR is trading above the MA-20 at $111.17 and the MA-50 at $109.14, while on the daily timeframe, it sits well above the MA-200 at $71.01. The Ichimoku Kijun on the daily timeframe is positioned at $110.85, providing immediate support. Momentum indicators are mixed: MACD is on Strong Buy, but ADX remains Neutral. The RSI reads 53.5, implying a mild buy bias, while Stoch RSI is Oversold, and CCI is Neutral. Bull/Bear Power reflects intraday buyer dominance, though overbought conditions persist, and the Awesome Oscillator is Neutral.

Upside favored as breakout risk shapes near-term outlook

Over the next two to three trading days, MNPR is projected to range between $106.20 and $116.32. Probability estimates indicate a 65% chance of further upside versus a 35% likelihood of retracement, suggesting upward moves are favored in the near term. The baseline scenario envisions price action holding within this sideways corridor, while a bullish scenario would require a sustained breakout above resistance. In contrast, a bearish scenario involves a break below immediate support, which could trigger a test of lower trading levels.

Anton Kharitonov, expert at Traders Union, views MNPR’s price action as technically resilient but lacking strong catalyst support. He emphasizes that mixed momentum signals and overbought intraday conditions limit conviction for aggressive entry. The analyst remains cautious given absent news and a sideways bias in the near term. "With no new catalysts and conflicting signals, I prefer to stay defensive until MNPR establishes a clear direction beyond the $106.20–$116.32 range."

Earlier, analysts noted that Monopar Therapeutics was exhibiting strong bullish momentum supported by a firm technical structure despite periods of heightened intraday volatility. The latest mixed momentum signals and persistent buyer dominance suggest traders should closely monitor the $110.85 Kijun support level, as a decisive move above or below this threshold could define the prevailing scenario in the sessions ahead.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.